A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
Roland Rad(ING Direct), Allan Bradley(Granta Design (United Kingdom)), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Maren Hieber(TUM Klinikum), Pentao Liu(Hong Kong Science and Technology Parks Corporation), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Vincenzo Calvanese(University of California, Los Angeles), Carolyn Grove(The University of Western Australia), Lydia Kriegl(Ludwig-Maximilians-Universität München), Barbara Seidler(German Cancer Research Center), Ignacio Varela(Wellcome Sanger Institute), Fernando Constantino‐Casas(University of Cambridge), Mario F. Fraga(Centre National de la Recherche Scientifique), Stacey Price(Wellcome Sanger Institute), Ultan McDermott(AstraZeneca (United Kingdom)), Günter Schneider(TUM Klinikum), Alexander Strong(Wellcome Sanger Institute), Hannes Ponstingl(Wellcome Sanger Institute), Dieter Saur(German Cancer Research Center), Wei Wang(Wellcome Sanger Institute), Roland M. Schmid(Tumkur University), Stefan Eser(TUM Klinikum), Gary J. Hoffman(The University of Western Australia), Kosuke Yusa(Kyoto University), Lena Rad(TUM Klinikum), Juan Cadiñanos(Universidad de Oviedo)
Cited by 216
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k